MTCL1

Across TCGA pan-cancer cohorts, MTCL1 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of MTCL1’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where MTCL1 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types MTCL1 is over-expressed in tumor, although a few such as COAD and PDAC show the opposite, repressed pattern.

CCRCC, COAD, and HNSC are the cancer types where MTCL1 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MTCL1 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	All	+1.009	<.001	12	view →
COAD	All	All	−1.176	<.001	8	view →
HNSC	Male	III,IV	+0.853	<.001	8	view →
LSCC	Male	II,III,IV	+0.799	<.001	8	view →
LUAD	Male	II,III,IV	+0.500	<.001	6	view →
PDAC	Male	II,III,IV	−0.319	.041	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

MTCL1–CCRCC

Open the CCRCC breakdown →